Movement Disorders (revue) - Checkpoint (Ncbi)

Index « Mesh.i » - entrée « Psychotic Disorders »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Psychotherapy, Rational-Emotive < Psychotic Disorders < Psychotropic Drugs  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 50.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000137 (1999) W. Meissner [Allemagne] ; T. Schmidt ; A. Kupsch ; T. Trottenberg ; T. LempertReversible leucopenia related to olanzapine.
000631 (2001) P J Reading [Royaume-Uni] ; A K Luce ; I G MckeithRivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial.
000685 (2002) Stewart A. Factor ; Eric S. Molho ; Joseph H. FriedmanRisperidone and Parkinson's disease.
000878 (2002) Drugs to treat dementia and psychosis: management of Parkinson's disease.
000A55 (2003) Hubert H. Fernandez [États-Unis] ; Martha E. Trieschmann ; Monica A. Burke ; Carol Jacques ; Joseph H. FriedmanLong-term outcome of quetiapine use for psychosis among Parkinsonian patients.
000B39 (1992) E. Pourcher [Canada] ; B. Gomez-Mancilla ; P J BédardEthosuximide and tremor in Parkinson's disease: a pilot study.
000B56 (2003) Werner Poewe [Autriche]Psychosis in Parkinson's disease.
000C42 (2003) Jan Herzog [Allemagne] ; Julia Reiff ; Paul Krack ; Karsten Witt ; Bettina Schrader ; Dieter Müller ; Günther DeuschlManic episode with psychotic symptoms induced by subthalamic nucleus stimulation in a patient with Parkinson's disease.
000C87 (2004) Mark Guttman [Canada] ; Pamela M. Slaughter ; Marc-Erick Theriault ; Donald P. Deboer ; C David NaylorParkinsonism in Ontario: comorbidity associated with hospitalization in a large cohort.
000E77 (2004) Hubert H. Fernandez [États-Unis] ; Edward M. Donnelly ; Joseph H. FriedmanLong-term outcome of clozapine use for psychosis in parkinsonian patients.
001022 (2005) Hubert H. Fernandez [États-Unis] ; Martha E. Trieschmann ; Michael S. OkunRebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease.
001191 (2005) Spiridon Papapetropoulos ; Deborah C. MashThe neurochemical mechanism of rebound psychosis in Parkinson's disease.
001220 (2005) Charles H. Adler [États-Unis]Nonmotor complications in Parkinson's disease.
001510 (2006) Kazumasa Suzuki ; Shuichi Awata ; Kae Nakagawa ; Takehisa Takano ; Hiroo MatsuokaCatatonic stupor during the course of Parkinson's disease resolved with electroconvulsive therapy.
001611 (2006) Gabriela Gonzalez Aleman ; Néstor Florenzano ; Eduardo Padilla ; Mercedes Bourdieu ; Gonzalo Guerrero ; María Calv ; Germán Alberio ; Sergio Strejilevich ; Gabriel A. De ErausquinA 37-year-old woman with celiac disease, recurrent psychosis, and Parkinsonism.
001640 (2006) Delia Lorenz [Allemagne] ; Daniel Schwieger ; Hans Moises ; Günther DeuschlQuality of life and personality in essential tremor patients.
001769 (2006) Mirdhu Wickremaratchi ; Huw R. Morris ; Imad M. AliAripiprazole associated with severe exacerbation of Parkinson's disease.
001813 (2006) Carles Gaig [Espagne] ; Maria José Martí ; Eduardo Tolosa ; Francesc Valldeoriola ; Pilar Paredes ; Francisco Juan Lome A ; Fernando Nakamae123I-Ioflupane SPECT in the diagnosis of suspected psychogenic Parkinsonism.
001831 (2006) Naomi P. Visanji [Canada] ; Jordi Gomez-Ramirez ; Tom H. Johnston ; Donna Pires ; Valerie Voon ; Jonathan M. Brotchie ; Susan H. FoxPharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
001871 (2006) Joseph H. Friedman [États-Unis] ; Robert M. Berman ; Christopher G. Goetz ; Stewart A. Factor ; William G. Ondo ; Joanne Wojcieszek ; William H. Carson ; Ronald N. MarcusOpen-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.
001890 (2007) Jose M. Rabey [Israël] ; Tatiana Prokhorov ; Ala Miniovitz ; Eugenia Dobronevsky ; Colin KleinEffect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Mesh.i -k "Psychotic Disorders" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/Mesh.i  \
                -Sk "Psychotic Disorders" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Ncbi
   |étape=   Checkpoint
   |type=    indexItem
   |index=    Mesh.i
   |clé=    Psychotic Disorders
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024